GlassScriptPhysician profile
Susan K Ziglar
NPI 1134102353
$3,641.80
in general payments reported to CMS, 2019-2025
30 companies · $708 in 2025
The $708 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $143 · 2021: $182 · 2022: $183 · 2023: $1,179 · 2024: $918 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,805.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,105.79 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $480.95 | 2023-2024 | Vraylar |
| Lilly USA, LLC | $313.63 | 2022-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $311.76 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $198.24 | 2022-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.92 | 2019-2024 | Jardiance, Tradjenta |
| Mylan Specialty L.P. | $106.81 | 2022-2023 | Yupelri |
| Novo Nordisk INC | $103.77 | 2019-2025 | Wegovy, Ozempic, Saxenda |
| Takeda Pharmaceuticals U.S.A., INC. | $103.54 | 2020-2021 | |
| Abbott Laboratories | $88.12 | 2021-2023 | Proclaim |
| Novartis Pharmaceuticals Corporation | $82.10 | 2019 | |
| Pfizer INC. | $76.76 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $74.58 | 2025 | Caplyta |
| Amgen INC. | $60.88 | 2020-2025 | Repatha, Otezla, Repatha |
| Aimmune Therapeutics, INC. | $58.67 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $48.03 | 2021-2025 | Contrave |
| Otsuka America Pharmaceutical, INC. | $43.39 | 2025 | Rexulti |
| Dynavax Technologies Corporation | $36.58 | 2025 | Heplisav-B |
| Insulet Corporation | $30.56 | 2019 | |
| Nevro Corp. | $28.32 | 2024 | Senza |
| Esperion Therapeutics, INC. | $23.86 | 2021 | |
| Astellas Pharma US INC | $22.66 | 2019 | |
| Glaxosmithkline, LLC. | $21.09 | 2024 | Shingrix |
| Viatris Specialty LLC | $20.86 | 2025 | Yupelri |
| Medtronic, INC. | $20.75 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.22 | 2022 | |
| Smith+Nephew, INC. | $15.14 | 2025 | Collagenase Santyl |
| Genentech USA, INC. | $14.20 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.75 | 2025 | |
| Janssen Pharmaceuticals, INC | $11.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Ziglar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.